<DOC>
	<DOCNO>NCT01598090</DOCNO>
	<brief_summary>The purpose study determine whether Peginterferon Lambda-1a ( Lambda ) combine Ribavirin ( RBV ) Telaprevir ( TVR ) effective treatment chronic Hepatitis C ( CHC ) compare Peginterferon Alfa-2a ( alfa-2a ) combine RBV Telaprevir .</brief_summary>
	<brief_title>Phase 3 Efficacy Safety Study Peginterferon Lambda-1a Ribavirin With Telaprevir</brief_title>
	<detailed_description>Data Monitoring Committee appoint Part B Masking : Part A : Open Label Part B : Double Blind</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Chronic hepatitis C genotype 1 . GT1b Capped 50 % naïve subject Naives prior antiHCV therapy [ Interferon ( IFN ) direct antiviral agent ( DAA ) base ] Relapsers ( define subject undetectable HCV ribonucleic acid ( RNA ) prior treatment regimen alfa2a/RBV Hepatitis C Virus ( HCV ) RNA &gt; 25IU/mL discontinuation treatment ) . Capped 20 % HCV RNA ≥ 100,000 IU/mL Subjects compensate cirrhosis enrol cap approximately 10 % Seronegative human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( HBsAg ) Men woman , 1870 year age Chronic liver disease due cause chronic HCV Current past evidence decompensation Conditions preclude use Alfa/RBV/TVR per respective label Diagnosed suspect hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>